Kestra Medical Technologies (NASDAQ:KMTS) Issues Quarterly Earnings Results, Misses Expectations By $0.61 EPS

Kestra Medical Technologies (NASDAQ:KMTS) released its earnings results on Monday. The company reported ($1.25) EPS for the quarter, missing the consensus estimate of ($0.64) by ($0.61), RTT News reports. During the same period in the previous year, the firm earned ($1.18) EPS. Kestra Medical Technologies updated its FY 2025 guidance to EPS.

Kestra Medical Technologies Stock Down 1.9 %

Shares of NASDAQ:KMTS opened at $23.83 on Tuesday. Kestra Medical Technologies has a 52 week low of $20.00 and a 52 week high of $26.06.

Wall Street Analyst Weigh In

KMTS has been the topic of a number of research reports. Stifel Nicolaus initiated coverage on shares of Kestra Medical Technologies in a research report on Monday, March 31st. They set a “buy” rating and a $28.00 target price on the stock. Wells Fargo & Company initiated coverage on shares of Kestra Medical Technologies in a research note on Monday, March 31st. They issued an “overweight” rating and a $28.00 target price for the company. Piper Sandler started coverage on shares of Kestra Medical Technologies in a research note on Monday, March 31st. They issued an “overweight” rating and a $27.00 target price for the company. Bank of America began coverage on Kestra Medical Technologies in a research report on Monday, March 31st. They issued a “buy” rating and a $30.00 target price on the stock. Finally, The Goldman Sachs Group started coverage on Kestra Medical Technologies in a research report on Monday, March 31st. They set a “neutral” rating and a $24.00 price target for the company. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $27.67.

Kestra Medical Technologies Company Profile

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution.